As future pharmacists and healthcare professionals, it is important for us to stay updated on new therapies, understand their counseling points, safety considerations, contraindications, and appropriate patient selection
The TGA says using these products raises significant regulatory and public health risks, stating it is actively monitoring this issue from both safety and law enforcement perspectives
Liraglutide has more years of post-market safety data (since 2010), but tirzepatide clinical trials involved large patient populations with rigorous safety monitoring
According to KFF analysis of Centers for Medicare & Medicaid Services 2018-2022 Medicare Part D spending by drug increased from $57 Million to $5.7 Billion.[2] The June 13, 2024 article in Fierce Healthcare[3] on GLP-1 drugs noted that Blue Cross Blue Shield of Michigan will no longer cover these drugs starting in January 2025, and will be changing the prior authorization criteria starting in August 2024, for those members that are in large group fully insured commercial plans
